Anzeige
Mehr »
Montag, 02.02.2026 - Börsentäglich über 12.000 News
KI für Verteidigung: Der Countdown zu einer der heißesten AI-Hightech-Stories 2026 beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
02.02.26 | 13:26
29,200 Euro
+1,39 % +0,400
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
28,90029,10013:37
28,80029,10013:28

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTeva snaps six straight sessions of gains28
Do11 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know40
DoTEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth27
DoWhat Makes Teva Pharmaceuticals (TEVA) a Successful Brand?11
TEVA Aktie jetzt für 0€ handeln
DoAfter a threefold rally, Teva faces its next test19
DoTruist Securities raises Teva Pharma stock price target to $38 on pipeline potential21
MiTeva Pharma stock price target raised to $37 from $36 at BofA Securities20
MiWed: Teva lower as TASE falls4
MiTeva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook11
MiTeva, after third straight year of growth, expects downturn in 20264
MiTeva Q4 2025 presentation: Revenue growth continues as innovative drugs shine8
MiTeva Pharm Q4 2025: Umsatzwachstum durch innovative Medikamente, Aktie dennoch unter Druck30
MiTeva's 2026 forecast disappoints despite strong finish to 202525
MiTeva sees lower revenue and profit in 202632
MiTeva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook319 PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable...
► Artikel lesen
MiEarnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast18
MiTeva projects revenue drop in 2026 despite Q4 beat8
MiTEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K, Current Report9
MiTeva Pharmaceutical Industries Ltd: Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential1.444Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding...
► Artikel lesen
MiTeva Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.32, revenue of $4.71B beats by $380M19
Weiter >>
247 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,1,11